(Reuters) - As Turing Pharmaceuticals Chief Executive Officer Martin Shkreli contends with charges of securities fraud, major U.S. pharmacies are moving to assure patients of continued access to the company's key drug, Daraprim.
http://ift.tt/1OcbrAA
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire